Daily non-political popular news in brief.
Disability from long-term rheumatoid arthritis reduced with biologic treatment
06-12-2007 · EurekAlert!New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
Read more »
Keywords: disability, long-term, rheumatoid, arthritis, reduced, biologic, treatment, long, term, arthriti
« Previous | Next »
Similar news on "Disability from long-term rheumatoid arthritis reduced with biologic treatment":
- Risk of lymphoma in rheumatoid arthritis decreased by long-term treatment with steroids
06-14-2007 · EurekAlert!
Two years or more of oral steroid treatment decreases the risk of rheumatoid arthritis related lymphoma, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology, in Barcelona, Spain. Furthermore, these effects were found regardless of when in the course of the disease the steroids were first administered. However, these beneficial effects were not observed if the steroids were taken for less than a two-year period.
Similar news · Read more »
- Biologic treatment for rheumatoid arthritis and the risk of cancer
08-29-2007 · EurekAlert!
Findings of various clinical trials and observational studies conflict over the risk of malignancy related to the use of tumor necrosis factor alpha blockers.
Similar news · Read more »
- Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
11-13-2006 · EurekAlert!
Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Similar news · Read more »
- Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
06-13-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.
Similar news · Read more »
- Latest data shows MabThera provides significant, sustained relief from symptoms of RA
06-13-2007 · EurekAlert!
New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
Similar news · Read more »
- New study reveals gender disparity in anti-TNF treatment for rheumatoid arthritis
06-14-2007 · EurekAlert!
Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis. Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs -- very effective but expensive modern medications against this disease -- at a higher perceived level of disease activity, and when they are reporting more severe pain than their male counterparts.
Similar news · Read more »
- Geisinger rheumatologists redesign osteoporosis, rheumatoid arthritis care
11-16-2007 · EurekAlert!
Geisinger Health System recently improved the ordering process for DXA scans, more than quadrupling the number of patients who received a bone density test for osteoporosis. Testing for the painful disease is the first step in getting care to patients. Details of the new program were presented at the recent American College of Rheumatology conference, along with results of three other studies that cast new light osteoporosis and rheumatoid arthritis treatment.
Similar news · Read more »
- First prospective study shows improvement of rheumatoid arthritis during pregnancy
06-14-2007 · EurekAlert!
Disease activity in patients with rheumatoid arthritis is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, RA improved significantly from the first trimester to the third trimester of the participants' pregnancy and this effect extended into the postpartum stage.
Similar news · Read more »
- Rheumatologists overestimate physical disability of rheumatoid arthritis patients
06-28-2007 · EurekAlert!
Rheumatologists substantially overestimate the physical disability of patients with rheumatoid arthritis, which may lead to inaccurate evaluations of patients' ability to work and need for lifestyle modifications, a new study found.
Similar news · Read more »
- Combining medications often best strategy to battle rheumatoid arthritis
11-19-2007 · EurekAlert!
For patients with rheumatoid arthritis, combining one well-known, lower-cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.
Similar news · Read more »
